ScholarX: OH, DONG RYUL

Detailed Information

OH, DONG RYUL (오동렬)

Medicine (Medicine)

Research Area

Tel 02-6007-5439
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Radiotherapy:13||Radiation therapy:10||Proton beam therapy:7||Esophageal cancer:6||Survival:6||Proton therapy:4||Oesophageal cancer:4||3:4||Neoadjuvant chemoradiotherapy:4||Quality of life:3||Squamous cell carcinoma:3||Prognosis:3||prognosis:3||proton therapy:3||Reirradiation:3||Esophageal neoplasms:3||3D printing:3||Parotid neoplasms:2||concurrent chemoradiotherapy:2||Neoadjuvant therapy:2||Neoadjuvant treatment:2||Neoplasm metastasis:2||Patientreported outcomes:2||Salvage therapy:2||Sarcopenia:2||Skeletal muscle loss:2||Chemoradiotherapy:2||Metastasis:2||radiation therapy:2||radiotherapy:2||Intensitymodulated radiation therapy:2||Duodenum:2||Esophageal Neoplasms:2||Surgery:2||head and neck:2||Prevention:2||Optimization:2||Probability:2||Hypofractionation:2||Lymph node:2||Tomotherapy:2||inflammation:2||Head and neck cancer:2||nasopharyngeal cancer:2||Treatment:2||Treatment outcome:2||Treatment planning:2||Nasopharyngeal carcinoma:2||Lymphoma:2||Validation:2||Outcomes:2||PET/CT:2||Radiodermatitis:2||PROCTCAE:2||Bragg peak:2||Machine learning:2||Palliative care:2||chemoradiotherapy:2||Hypofractionation:1||Hypopharyngeal carcinoma:1||Hypopharyngeal neoplasms:1||Immune checkpoint inhibitor:1||Immunotherapy:1||Induction chemotherapy:1||Intensitymodulated radiotherapy:1||Key words NK/Tcell lymphoma:1||Korea:1||Korean Translation:1||Laryngeal preservation:1||Laser:1||Liquid biopsy:1||Locally advanced:1||Locoregional recurrence:1||Locoregional neoplasm recurrence:1||Locoregional recurrence:1||Logistic regression:1||Low muscle mass:1||Low or highvolume:1||Lowlevel laser therapy:1||Lung cancer:1||Lymphatic irradiation:1||MHealth:1||Malnutrition:1||Marginal zone Bcell lymphoma:1||Measurement scale:1||Methotrexate:1||Minimal involvement:1||Mobile app:1||Mobile application:1||Mobile health:1||Muscle loss:1||NUT carcinoma:1||Nasopharyngeal cancer:1||Nasopharyngeal neoplasms:1||Neck:1||Negative predictive value:1||Neoadjuvant chemoradiation:1||Non small cell lung cancer:1||Nonsmall cell lung cancer:1||Nonsmall cell lung carcinoma:1||Nuclear medicine:1||Nutrition:1||Oesophageal carcinoma:1||Oesophageal fistula:1||Olaparib:1||Oligometastasis:1||Oncologic outcome:1||Oropharyngeal cancer:1||Oropharyngeal neoplasms:1||Oropharynx:1||PROMIS:1||PROMIS29:1||PatientCentered Care:1||PatientReported Outcomes:1||PatientReported Outcomes Measurement Information System:1||Patientderived cell:1||Patientreported outcome:1||Performancebased task ability:1||Photobiomodulation:1||Photobiomodulation therapy:1||Polymetastasis:1||Positron emission tomography:1||Positron emission–computed tomography:1||Postoperative complication:1||Postradiation nasopharyngeal necrosis:1||Precision medicine:1||Progressionfree survival:1||Protocols & guidelines:1||Pulmonary complication:1||RCHOP:1||Radiation:1||Radiation field:1||Radiationinduced:1||Radiationinduced complication:1||Radiosurgery:1||Radiotherapy dosage:1||Randomized Controlled Trial:1||Randomized controlled trial:1||Realworld data:1||Recurrence:1||Refusal:1||Risk factors:1||Salivary gland cancer:1||Salivary gland neoplasms:1||Salvage radiotherapy:1||Skin:1||Small cell lung cancer:1||Small cell lung carcinoma:1||Spinal neoplasms:1||Squamous cell carcinoma of head and neck:1||Standardized uptake value:1||Stomach:1||Surgical indications:1||Surveillance:1||Symptom monitoring:1||Systemic metastasis:1||T cell senescence:1||T4b oesophageal cancer:1||Threedimensional conformal radiotherapy:1||Thymic tumor:1||Tongue displacement:1||Tongue immobilization device:1||Tool development:1||Toxicity:1||Tremelimumab:1||Tumor spheroids:1||Volumebased:1||acute toxicity:1||adenoid cystic carcinoma:1||adjuvant radiation therapy:1||aged:1||brachytherapy:1||cancer recurrence:1||central nervous system:1||cervical cancer:1||chemoradiation:1||circadian rhythm:1||complication:1||concurrent chemoradiation:1||consolidation therapy:1||consolidative radiation therapy:1||deep neural network:1||definitive radiation therapy:1||diagnostic value:1||diffuse large B cell lymphoma:1||diffuse large Bcell lymphoma:1||distant metastasis:1||dry mouth:1||durvalumab:1||eHealth:1||eeliability:1||efficacy index:1||esophageal cancer:1||esophageal squamous cell carcinoma:1||great vessel invasion:1||head and neck cancer:1||head and neck cancers:1||head and neck squamous cell cancer:1||helical tomotherapy:1||intensitymodulated proton therapy:1||intensitymodulated radiotherapy:1||lung cancer:1||lymph node dissection:1||lymphocyte:1||mHealth:1||machine learning:1||mortality:1||mouse model:1||nasal cavity:1||nasopharyngeal neoplasms:1||neoadjuvant chemoradiation therapy:1||neoadjuvant chemoradiotherapy:1||neutrophil:1||neutrophiltolymphocyte ratio:1||nonsmall cell lung cancer:1||nonsmall cell lung carcinoma:1||nuclear protein in testis:1||nutrition:1||oral mucosa:1||orbital MALT lymphoma:1||organs at risk:1||oropharyngeal cancer:1||oropharynx:1||paranasal sinus:1||patientreported outcomes:1||pattern of failure:1||patterns of care:1||peripheral blood:1||pharyngeal cancer:1||phlorotannins:1||platelettolymphocyte ratio:1||poorly differentiated carcinoma:1||positron emission tomography (PET):1||prevalence:1||prophylactic cranial irradiation:1||proton beam stopper:1||radiation:1||radiation dermatitis:1||radiation injury:1||radiation pneumonitis:1||radiotherapy treatment planning:1||salivary gland:1||sarcopenia:1||skeletal muscle loss:1||small cell lung cancer:1||smallcell lung cancer:1||squamous esophageal cancer:1||surveillance:1||survival:1||survival outcome:1||symptom:1||symptomatic adverse events:1||systemic inflammatory markers:1||target volume:1||testis:1||tongue displacement device:1||treatment:1||tremelimumab:1||<sup>18</sup>FFDG PET/CT:1||validity:1||2:1||2613278:1||2614923532237076502700:1||2615661484407316:1||2813186655:1||281318970511350:1||28342468462712644:1||5:1||61346781469094:1||8:1||Abscopal effect:1||Acute toxicity:1||Adjuvant chemotherapy:1||Adoption:1||Base of tongue cancer:1||Blood test:1||Bone marrow:1||CHEMOTHERAPY:1||CROSS:1||Cancer:1||Cancer patients:1||Cellfree DNA:1||Central nervous system:1||Central tumors:1||Chemotherapy:1||Combination index:1||Compliance:1||Concurrent chemoradiotherapy:1||Conjunctiva:1||Deescalation:1||Deauville score:1||Definitive radiotherapy:1||Diabetes mellitus:1||Diffuse large Bcell lymphoma:1||Digital health literacy:1||Digital health technology literacy:1||Distress:1||Durvalumab:1||EGFRTKIs targeted therapy:1||Early stage esophageal cancer:1||Elderly:1||Endoscopic debridement:1||Esophageal toxicity:1||Evidencebased practice:1||Extensivestage:1||F18fluorodeoxyglucose:1||FDGPET:1||Failure pattern:1||Follicular lymphoma:1||Fractures, compression:1||Head and neck neoplasm:1||Head and neck neoplasms:1||Hepatocellular carcinoma:1||Highthroughput screening platform:1||Histology:1||Hospital:1||Human papillomavirus:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE